Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nanobiotix (NBTX) Liabilities and Shareholders Equity (2018 - 2025)

Nanobiotix has reported Liabilities and Shareholders Equity over the past 8 years, most recently at $78.9 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 9.48% year-over-year to $78.9 million; the TTM value through Dec 2025 reached $295.4 million, down 4.84%, while the annual FY2025 figure was $78.9 million, 9.48% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $78.9 million at Nanobiotix, up from $51.1 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $149.2 million in Q2 2021 and troughed at $44.0 million in Q2 2023.
  • A 5-year average of $85.3 million and a median of $82.5 million in 2022 define the central range for Liabilities and Shareholders Equity.
  • Biggest five-year swings in Liabilities and Shareholders Equity: plummeted 48.86% in 2023 and later skyrocketed 112.15% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $116.4 million in 2021, then plummeted by 47.62% to $61.0 million in 2022, then skyrocketed by 65.68% to $101.0 million in 2023, then fell by 28.69% to $72.0 million in 2024, then increased by 9.48% to $78.9 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for NBTX at $78.9 million in Q4 2025, $51.1 million in Q2 2025, and $72.0 million in Q4 2024.